Secretion of <scp>IL</scp>‐1β from imatinib‐resistant chronic myeloid leukemia cells contributes to <i>BCR</i>–<i>ABL</i> mutation‐independent imatinib resistance

Lee, Cho-Rong; Kang, Jung‐Ah; Kim, Hye-Eun; Choi, Yegyun; Yang, Taewoo; Park, Sung‐Gyoo

doi:10.1002/1873-3468.12057

Cited by 17 publications

(7 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…39 These insights are useful as clinical studies are designed on IL-1 inhibition as means to overcome TKI resistance and eradicate the LSCs in CML. 37,39,68 The strong evidence on IL-1 and IL-6 signaling in the tumor microenvironment has generated interest in IL-1 inhibition in the clinical setting of MM. Lust et al were the first to perform a proofof-concept trial on IL-1 inhibition in patients diagnosed with a hematological malignancy.…”

Section: Pathophysiological Mechanismsmentioning

confidence: 99%

Targeting the interleukin-1 pathway in patients with hematological disorders

Mooij¹,

Netea

Velden³

et al. 2017

Blood

View full text Add to dashboard Cite

Interleukin-1α (IL-1α) and IL-1β are potent inflammatory cytokines that activate local and systemic inflammatory processes and are involved in protective immune responses against infections. However, their dysregulated production and signaling can aggravate tissue damage during infection, inflammatory diseases, and chemotherapy-induced intestinal mucositis. Additionally, cytokines of the IL-1 family play an important role in homeostatic as well as "emergency" hematopoiesis and are involved in the pathogenesis of several myeloid and lymphoid hematological malignancies. In the pathogenesis of intestinal mucositis and graft-versus-host disease (GVHD), these cytokines are considered pivotal during the initiation as well as propagation phase, and insights from animal studies suggest that targeting the IL-1 pathway can significantly ameliorate mucositis and GVHD. Moreover, IL-1α and IL-1β might prove to be valuable targets for both prevention and treatment of cancer and cancer therapy-related complications, and the first clinical studies have already been performed in the setting of hematological malignancies. In this review, we will discuss the role of cytokines of the IL-1 family in hematological malignancies, chemotherapy-induced intestinal mucositis, and GVHD, and speculate on possibilities of therapeutically targeting the IL-1 pathway in hematological patients.

show abstract

Section: Pathophysiological Mechanismsmentioning

confidence: 99%

Targeting the interleukin-1 pathway in patients with hematological disorders

Mooij¹,

Netea

Velden³

et al. 2017

Blood

View full text Add to dashboard Cite

show abstract

“…IL-6 significantly contributes to MAS. Its levels increase with the severity of COVID-19 (9,19,20) and the area of pulmonary infiltration (>50%) in patients with ARDS, together with specific lymphocyte subsets (21). Though the present case had received tocilizumab prior to canakinumab, IL-6 level remained high, postulating that tocilizumab be insufficient to rescue the patient from the subsequent cytokine storm.…”

Section: Figure 2 | (A)mentioning

confidence: 61%

Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome

et al. 2020

View full text Add to dashboard Cite

Severe cases of COVID-19 present with serious lung inflammation, acute respiratory distress syndrome and multiorgan damage. SARS-CoV-2 infection is associated with high cytokine levels, including interleukin-6 and certain subsets of immune cells, in particular, NK, distinguished according to the cell surface density of CD56. Cytokine levels are inversely correlated with lymphocyte count, therefore cytokine release syndrome may be an impediment to the adaptive immune response against SARS-CoV-2 infection. Canakinumab, a monoclonal antibody targeting IL-1β is under investigation for the treatment of severe SAR-CoV-2 infection. An 85 year old male presenting in our hospital with COVID-19, whose condition was complicated by acute respiratory distress syndrome and cardiac and renal failure (with oliguria) after 25 days of hospitalization, was intubated and received canakinumab for compassionate use. On the next day, diuresis recovered and conditions improved: high IL-6 levels and NK cells expressing CD56 bright (associated with cytokine relase) were significantly reduced giving rise to NK CD56 dim . Patient died on day 58 with pulmonary bacterial superinfection and persistent SARS-CoV-2 positivity. In conclusion, canakinumab rescued a high risk, very elderly patient, from multiorgan damage complicating COVID-19. It may represent an useful treatment in severe cases.

show abstract

“…Therefore, it is crucial to enhance the chemosensitivity of NSCLC cells to paclitaxel. IL-1β is involved in drug resistance or chemosensitivity (15)(16)(17); however, to the best of our knowledge, there are few studies on the association between IL-1β and paclitaxel. For example, IL-1β expression is upregulated in macrophages as a response to paclitaxel chemotherapy (29).…”

Section: Discussionmentioning

confidence: 99%

“…High serum IL-1β level in NSCLC is associated with short overall survival (14). In addition, IL-1β is associated with resistance to cancer drugs, such as cisplatin (15), 5-fluorouracil (16) and imatinib (17). However, to the best of our knowledge, the association between IL-1β and paclitaxel resistance in NSCLC remains largely unknown.…”

Section: Introductionmentioning

confidence: 99%

Interleukin‑1β weakens paclitaxel sensitivity through regulating autophagy in the non‑small cell lung cancer cell line A549

Lian

Tao

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) poses a threat to human health and paclitaxel chemotherapy has been approved for the treatment of this type of cancer. However, resistance to treatment severely compromises the survival rate and prognosis of patients with NSCLC. The aim of the present study was to investigate the role of IL-1β in paclitaxel sensitivity of NSCLC cells and elucidate the underlying mechanism. The expression of IL-1β was found to be upregulated in NSCLC tissues and cells compared with healthy adjacent tissues and a normal epithelial cell line, respectively, as detected by reverse transcription-quantitative PCR and western blot analyses. Subsequently, Cell Counting Kit-8 assay and flow cytometry revealed that IL-1β weakened the sensitivity of A549 cells to paclitaxel. It was subsequently demonstrated that IL-1β induced A549 cell autophagy, while tunicamycin-induced autophagy increased the IL-1β expression level and weakened paclitaxel sensitivity. Thus, the results revealed that IL-1β reduced the sensitivity to paclitaxel in A549 cells by promoting autophagy and suggested that IL-1β may be of value for improving the therapeutic efficacy of paclitaxel chemotherapy in NSCLC.

show abstract

Secretion of IL‐1β from imatinib‐resistant chronic myeloid leukemia cells contributes to BCR–ABL mutation‐independent imatinib resistance

Cited by 17 publications

References 50 publications

Targeting the interleukin-1 pathway in patients with hematological disorders

Targeting the interleukin-1 pathway in patients with hematological disorders

Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome

Interleukin‑1β weakens paclitaxel sensitivity through regulating autophagy in the non‑small cell lung cancer cell line A549

Contact Info

Product

Resources

About